InvestorsHub Logo
Followers 77
Posts 2527
Boards Moderated 1
Alias Born 12/04/2020

Re: Nelson2 post# 3294

Sunday, 02/21/2021 6:58:20 AM

Sunday, February 21, 2021 6:58:20 AM

Post# of 9432
MindMed is unique in that they aren't shroom centered. There are now literally like 20 companies going for the biggest slice of the shroom pie. The competition will really bog that part of the psychedelic sector down. MindMed, with their Ibogaine, LSD, MDMA, etc., derivatives are a breed apart. Combine that with their hard push into the digital dosing/administration/treatment aspect, and they will dominate.

I hate to say it, but likely 90% of the psychedelic start-ups currently in business will not exist in 4-5 years. They will shine their shareholders on for years, convincing them they have something unique to offer, but in the end they will wither and close up shop.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MNMD News